In this era of new pharmacological combinations, drug triplets including VEN34, 35, 36 are a therapeutic modality currently being investigated for the treatment of AML to overcome resistance in patients with poor prognosis, especially those with TP53 mutations. The gene discussed is TP53; the disease is acute myeloid leukemia.